Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013.

Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per share.

Revenue The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $1.0 million versus $1.5 million, respectively. This NIAID contract, which provides up to $25.3 million of funding over seven years, is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for Q1 2013 were $5.1 million compared to $4.0 million for Q1 2012. This increase was primarily due to $788,000 in higher clinical expenses related to our ongoing HPV-003 clinical trial. General and administrative expenses were $3.0 million versus $2.5 million, respectively.

Net Loss Attributable to Common Stockholders The $590,000 increase in net loss for the comparable periods resulted primarily from an increase in operating expenses offset by a lower (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price.

Capital Resources As of March 31, 2013, cash and cash equivalents plus short-term investments were $28.2 million compared with $13.8 million as of December 31, 2012.

On March 7, 2013, we closed an underwritten offering of 27,377,266 shares of our common stock and warrants to purchase an agg
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... and CINCINNATI , ... plc (LSE: SHP, NASDAQ: SHPG ) and ... three-year, broad research collaboration for rare diseases. The goal ... novel therapies to treat rare diseases with high ... capabilities with Cincinnati Children,s research expertise. As a ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, ... at Align Technology, on “ Conducting Postmarket Registries - ... Global Conference and Exhibition on April 25th through April ... the poster presentation, Ale Gicqueau and Victor Chen will ... Registry, the requirements and resources to conduct the registry, ...
(Date:3/25/2015)... , March 25, 2015 Optimal Research, LLC ... Industry Excellence (ViE) Award "Best Clinical Site or Trial ... that Optimal has been selected as a nominee in ... receiving a "Highly Recommended" distinction in 2014. The ViE ... the efforts, accomplishments, and positive contributions of companies and ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... new market research report is available in its catalogue: , ... Global Nucleic Acid Testing Industry , , ... , , ... US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The ...
... , ... with Key Partners Recognized , ... Wilmington, Del. (Vocus) June 22, 2010 -- All three DuPont biofuels collaborations ... The DuPont Danisco Cellulosic Ethanol ( DDCE ) joint venture and the DuPont ...
... ... , ... 2010 -- iCardiac Technologies, Inc. , a provider of next generation cardiac core ... selected iCardiac as a preferred vendor. iCardiac will provide a full range of ...
Cached Biology Technology:Reportlinker Adds Global Nucleic Acid Testing Industry 2Reportlinker Adds Global Nucleic Acid Testing Industry 3Reportlinker Adds Global Nucleic Acid Testing Industry 4Reportlinker Adds Global Nucleic Acid Testing Industry 5Reportlinker Adds Global Nucleic Acid Testing Industry 6Reportlinker Adds Global Nucleic Acid Testing Industry 7Reportlinker Adds Global Nucleic Acid Testing Industry 8Reportlinker Adds Global Nucleic Acid Testing Industry 9Reportlinker Adds Global Nucleic Acid Testing Industry 10DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 2DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 3DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 4Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor 2
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/12/2015)... March 12, 2015 IriTech, a leading iris ... of the Texas Instruments Design Network, announced today that ... demonstrated its IriShield USB MK2120U device during a launching ... pension distribution. The iris scanner is ... marketed in India through its ...
(Date:3/11/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ... Control Market by Product, Application & By Geography - ... their offering. , This report predicts that ... billion by 2020, with an estimated CAGR of 10.6%. ... products types such as contact cards & readers, contactless ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... , , , , , ... AUDIO: When men outnumber women, the women tend to marry younger and men engage in riskier, ... , , , , , , ... , , , , , , , ANN ARBOR, Mich..---When men outnumber women, ...
... molecule known to be involved in progressive heart failure ... damage after a heart attack, according to researchers at ... conclusion, the research team used gene therapy to inhibit ... kinase 2 (GRK2), and found heart muscles cells in ...
... to grab a glass of milk when you,re on diet, suggests ... Nutrition . In a 2-year weight loss study, milk drinkers had ... that adults who drank the most milk (nearly 2 glasses per ... lost more weight after 2 years than those who had little ...
Cached Biology News:Women: Hope to marry young? Head to Alaska, steer clear of Alabama 2Women: Hope to marry young? Head to Alaska, steer clear of Alabama 3Women: Hope to marry young? Head to Alaska, steer clear of Alabama 4Molecule involved in heart failure now implicated in heart attack damage 2New study finds milk drinkers may have a healthy weight advantage 2
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
...
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Biology Products: